Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Guru Sonpavde MD
Guru P. Sonpavde MD Advisory Board
Oliver Sartor MD
Oliver Sartor MD Advisory Board
Alexander van Akkooi MD, PhD, FRACS
Alexander C. J. van Akkooi MD, PhD, FRACS Associate Editor
See All Experts
featured
Published in Oncology

Expert Opinion / Commentary · June 07, 2018

First-Line Treatment of Advanced NSCLC Without Driver Mutations—Is the Standard of Care Rapidly Changing?

Wilfried Eberhardt MD

 

 Save  Recommend
 Share

Additional Info

  1. Gandhi L, Rodríguez-Abreu D, Gadgeel S, et al. Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer. N Engl J Med. 2018;378(22):2078-2092.
  2. Lopes G, Wu Y-L, Kudaba I, et al. Pembrolizumab (pembro) versus platinum-based chemotherapy (chemo) as first-line therapy for advanced/metastatic NSCLC with a PD-L1 tumor proportion score (TPS) ≥ 1%: Open-label, phase 3 KEYNOTE-042 study. Paper presented at: American Society of Clinical Oncology Annual Meeting; May 31-June 4, 2018; Chicago, IL. Abstract LBA4.
  3. Paz-Ares LG, Luft A, Tafreshi A, et al. Phase 3 study of carboplatin-paclitaxel/nab-paclitaxel (Chemo) with or without pembrolizumab (Pembro) for patients (Pts) with metastatic squamous (Sq) non-small cell lung cancer (NSCLC). Paper presented at: American Society of Clinical Oncology Annual Meeting; May 31-June 4, 2018; Chicago, IL. Abstract 105.
  4. Jotte RM, Cappuzzo F, Vynnychenko I, et al. IMpower131: Primary PFS and safety analysis of a randomized phase III study of atezolizumab + carboplatin + paclitaxel or nab-paclitaxel vs carboplatin + nab-paclitaxel as 1L therapy in advanced squamous NSCLC. Paper presented at: American Society of Clinical Oncology Annual Meeting; May 31-June 4, 2018; Chicago, IL. Abstract LBA9000.
  5. Socinski MA, Jotte RM, Cappuzzo F, et al. Overall survival (OS) analysis of IMpower150, a randomized Ph 3 study of atezolizumab (atezo) + chemotherapy (chemo) ± bevacizumab (bev) vs chemo + bev in 1L nonsquamous (NSQ) NSCLC. Paper presented at: American Society of Clinical Oncology Annual Meeting; May 31-June 4, 2018; Chicago, IL. Abstract 9002.
  6. Borghaei H, Hellmann MD, Paz-Ares LG, et al. Nivolumab (Nivo) + platinum-doublet chemotherapy (Chemo) vs chemo as first-line (1L) treatment (Tx) for advanced non-small cell lung cancer (NSCLC) with <1% tumor PD-L1 expression: Results from CheckMate 227. Paper presented at: American Society of Clinical Oncology Annual Meeting; May 31-June 4, 2018; Chicago, IL. Abstract 9001.
  7. Hellmann MD, Ciuleanu TE, Pluzanski A, et al. Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden. N Engl J Med. 2018;378(22):2093-2104.

Further Reading

Most Read This Week

Recently Updated